Stephen Sideroff 00:01
Welcome to the resilient longevity podcast. I'm your host, Dr. Steven Sideroff and I'm joined by my co host, Dr. Rob Lufkin, Rob.
Robert Lufkin 00:12
Hey, Steve, it's great to be here. Telemedicine is finally coming to longevity. And today, we're joined by one of the experts in the field that is developing this space. Daniel Tawfik. Dan, welcome to the show.
Daniel Tawfik 00:29
Thank you so much, Rob. Steve, it's, it's great to be with you guys. It's exciting that this community is we're all getting together and talking about our favorite subjects, rap wise, and all the all the good stuff.
Robert Lufkin 00:44
Yeah, this is good. This is gonna be so much fun today. Yeah,
Daniel Tawfik 00:49
for sure.
Stephen Sideroff 00:50
Then why don't you begin by telling the audience how you got into this field? What, what intrigued you to step into this area?
Daniel Tawfik 01:01
Yeah. So my background, I went to UCLA studying molecular biology, I did some postgraduate work there. I was studying the intersection of Tor and neurodegenerative disorders. So particularly Alzheimer's and sort of the how the over activation of this cellular complex that dictates protein synthesis within the cell dictates when a cell is going to replicate release growth factor. How the over activation of that molecule was leading to these disease states in Alzheimer's, Parkinson's. And it was clear to me from this research that the way that we were manipulating that overactivation state was through diet. So we were providing these animal models, protein, particular abundance of an amino acid called leucine, to stimulate this, this Tor molecule, and we're seeing that the proportion of mice that were that when we over activated Tor had this disease, a higher proportion of Alzheimer's and Parkinson's disease. So when you're looking at it, you say, hey, you know, it looks like as as, as animals, we have more control over the biological levers of aging, then this is just something that happens. Aging is something that happens over time with wear and tear, there seems to be these, these evolutionary, this evolutionary programming that responds to lifestyle choices that we make, that either accelerates or decelerates aging. Most of that can be a function of lifestyle changes with diet and exercise, right? So. In our case, we were overstimulating tore through the administration of a lot of Leucine and the mice is Chow. But in humans observationally, we can see that there's this whole population of obese people that have a higher proportion of, of these age related chronic diseases and at younger and younger ages. So my thought was like if people can understand what the levers that they're playing with, so, you know, on a standard American diet, people are playing with the metabolic levers of consuming too much essentially more nutrients than than the cell needs. And it's overstimulating these, these pathways that lead to cellular growth in excess and dysfunction. If they can understand how they can manipulate those, those levers in their favor, they can start decelerating the progression of aging in lead to a life with an extended health span, meaning health span, the definition would be the time period of your life that you're not dealing with an age related chronic disease. We manipulated the outcome of what proportion of these animals had had this like had Alzheimer's or Parkinson's disease by also administrating pharmaceutical molecule. So in our case, it was Metformin. Eventually, we started playing around with rat mice and and we saw the augmentation of, we weren't seeing these mice end up in this end state of having these age related chronic diseases, these neurodegenerative disorders. So there's something about once you can modify these lifestyle pieces and supplementing with some of these pharmacological interventions as well, there's humans had more control over the aging process, then we would, would would think that sometimes, you know, we get the we get a terrible disease, and it's, it's a function of our genes. But it's also we have ways to diminish the likelihood that we have cardiovascular disease, we have neurodegenerative disease, we have cancer. Ultimately, the reason why we started our telemedicine practice was Well, I think in the research community, it's abundantly clear that there are these interventions at play that that are very interesting to us, whether they're taking some of these, these medications that have proven some benefit to longevity and lifespan. That pipeline from the research community to the clinical front line is definitely broken. Like I went to go see, I was interested in taking Metformin. Because I knew the research behind that for me when I want to talk to my PCP. My PCP thought it was crazy that a 35 year old want to take Metformin, right, let alone you know, immunosuppressant drug like mice. And
Stephen Sideroff 07:05
I had I had the same experience with my primary when I approached her with the similar question.
Daniel Tawfik 07:13
You're perfectly healthy, why would you want to take a medication for diabetes patients. And so we're looking at the landscape of options for people. It was clear that people that are intimately knowledgeable about the patients who are knowledgeable about what's happening in the research community didn't really have a clinical home, to go see a physician to see if taking some of these medications. were appropriate for them. So we wanted to create a clinical home for people that are interested in senescence as a driver of aging. We'll talk about that was one of these conserved evolutionary responses that seems to be driving aging, we created our telemedicine practice healthspan to solely focus on this one pathway, cellular senescence and Tor driven aging. And connecting patients with physicians and therapies to to attack this specific pathway of senescence formation. We just wanted to give those patients a home where they can go and actually find some find someone that they can talk to about taking these therapies. And, you know, also doing it in a very safe way or it's administered by a doctor and they're not ordering the medications from you have some lab or that unvetted and so let's just make that bring this to the mainstream in a way that it's it's it makes it safe for for patients. Yeah, this
Robert Lufkin 09:03
is such an interesting area. Before we dive in, maybe you could and you hinted at this a little bit before, but maybe you could just summarize kind of your, your approach to the way you conceptualize longevity and aging. Why do we age that kind of thing?
Daniel Tawfik 09:22
Yeah. So Aging has for longest time we thought of aging is kind of wear and tear. You use it, you abuse it, and eventually you get cellular degradation, right? If you think about aging as these these, these cellular programs, right? Is evolutionary conserved cellular programs, if you think about it, from the standpoint of what happens to a cell that has incurred some injury right A cell that is exposed to a carcinogen that has damage has Three Fates. So it can go through the process of apoptosis, which is cellular death. So across all of ourselves, there's multiple mechanisms where we can just kill in response to injury, the cell can self destruct, right? And when this happens, you know, billions of times. It's it's a healthy process when when you have injuries, and so you don't want it to replicate such that that injury, that dysfunction creates its own line. So you have a damaged cell line from that point. So the other, the other outcome is that that negative state which is tumorigenesis, right, so unmitigated growth on the cell keeps replicating the damage spreads. And then lastly, we have a way to, to there's another evolutionary conserve way to stop that tumorigenesis, which is senescence. So senescence is this state in which there's the there's Arrested Development, right? So your the cell is not allowed to replicate? It's, it's, it's, there's a blocker, it's cell cycle to when it's exposed to growth factor, it doesn't replicate, which is great, right? So you're stopping the harm that that can spread from that damage. So, but as we, as we age, we accumulate more and more of the senescence cells, right, in our body has, when we're young, we're able to kill senescence cells at a similar rate to the rate of which we're accumulating them. The problem was senescence cells is they, it's when they're exposed to this growth factor. They have they exhibit this what this deleterious effect that Mikael block is gonna cause hyperfunction. So they will grow, they exhibit something called hypertrophy, their surface area grows larger than a normal cell, right? So they're much larger than a healthy cell, which has implications that that cell now has preferred access to nutrients, right, so this damaged cell line as preferred x, it has more glute channels to get peripheral glucose into the cells over your healthy cells. It has exhibits something called hyperplasia, it releases it secretes more mitogenic factor and growth factor so it's growing adjacent cells in a way that's very unhealthy. And lastly, it has this hyperfunction So it's, it's it's your, your your secreting and creating more proteins, degraded proteins, dysfunctional, toxic proteins that are highly inflammatory, outside of the cell. And so you're basically if you look at most disease states, it's these diseases are a function of cellular access. So if you look at wrinkles in a in in humans, it's the the keratinocyte is producing too much keratin. In balding the there's too much androgens being produced this, this excess production neurodegeneration, which we started with it's it's overproduction of tau proteins, right, that's creating this inflammatory response. And so these senescence cells are a kind of become these like Frankenstein's monsters. They release all these inflammatory molecules, and they have this this characteristic called the The SASP. So the SAS was the senescence associated Secretary Secretary phenotype. If you look at a senescence cell around it, you would see a lot of inflammation right and that inflammation drives further transformation of healthy cells into senescence cells, and so the rate of transformation of healthy tissue and to dysfunctional tissue dysfunctional tissue accelerates, right. And so the idea is through metabolic processes through diet and exercise, things that you both are both very passionate about, we can modulate that that acceleration. And through supplementation with, with things like Metformin or rap mice. And you can also slow down that, that acceleration, that excess is driven by that molecule we started off started out with that title complex called Tor. And when Tor is, is presented with excess nutrients in the form of glucose and amino acids, it says hey, there's a lot of energy right? Now let's let's build this is what's going on growth phase let's, let's do a lot of protein synthesis. Let's let's, let's grow in the hypertrophy expansion. So if we can, through lifestyle measures through diet exercise, we can clamp that that or activity intermittently. So you don't want to always inactivate tors behavior, you want to do it separately. So that you get the benefits of cellular growth and certain phases of life. And you get the benefits of being in slightly catabolic state where you're, you're you're you're not getting this excessive cellular growth in your internally consuming some of these these harmful deleterious misfolded proteins. But it is to say that we have control over the formation of senescence cells through this lifestyle in pharmaceutical interventions.
Robert Lufkin 16:58
One quick follow up question is, you mentioned and we're going to talk more about lifestyle methods and also primarily about your program, with telemedicine with pharmaceutical methods for turning down Tor as a way to affect senescence and increase possibly longevity. In mentioning that, you you mentioned the usual thing, which is it Tor is a nutrient sensing program. So we want to avoid the nutrients that stimulate Tor. And there are two broad groups that you mentioned. And of course, everybody knows about carbohydrates and glucose sensing for Tor. So we want to lower the glucose spikes, and we'll talk about ways of doing that. But you also mentioned the other the branched chain amino acids, primarily things like leucine. And all. Do you think it's valuable? You know, in your work with the animal models as well, I haven't seen people talking about a low leucine diet or anything like that. What What's your take on that?
Daniel Tawfik 18:06
I would agree with that. I don't think there's there's debate on this. So it's not a it's not a clear cut. Answer here. But I don't think that people are consuming enough protein, oh, like eating, basically having an IV of amino acids to stimulate Tor all the time. I think that I think what the real concern is the standard American diet in which or there's excess carbohydrates are the real problem. We use leucine, because we knew that would that would stimulate Tor. And we knew that pathway, right? We don't think in human beings that if you're getting more than like three grams of Leucine a day, you're you're having unhealthy tore tore levels. That's a debatable thing, but we just don't have enough studies to to say that and I just don't I actually don't think it's a it's a very interesting study to have because that's not really is really like the nth degree. We have a glaring problem, which is a standard American diet and and excess carbohydrates. So I don't think this should be we get that question a lot should I should I withhold my protein intake if you're not eating enough protein, that you're getting these these hyper elevated act activity of Tor? So I don't think it's something that most patients have anything to worry about. So just
Robert Lufkin 19:52
to reiterate, underline that Leucine is an amino acid which makes up proteins total or can be stimulated by amino acids just like with carbohydrates, but in our diets, proteins are not really a problem. So most people are not advocating lowering proteins. The big offender for turning on Tor is carbohydrate. So, you know, we're going to talk more about a car bonus and other things. So if you want to turn down, tore scratch the orange juice, scratch the sugar in your coffee, scratch the, you know, the bread and pastries and all those things. And the carbohydrates are really the way to go at least is that what you're saying?
Daniel Tawfik 20:38
Yeah, you're not eating enough. So that again, the reason why Leucine is of interest for these folks and labs is leucine binds to, to mTOR. And it activated v as Tor is a nutrient sensing compound within the within the cell. It's really sensing glucose levels through through its its downstream kind of energy unit, which is ATP. And, and leucine as an amino acid can say, Okay, we have a lot of building blocks here. Let's start, let's start building it's a great time for growth, right? Like we have the human just ate a lot of food, well, let's start let's start growing, right? Leucine is is an amino acids that triggered mTOR. That's the only that's the only significance of that. But human beings are not eating enough protein systemically, and we're not absorbing enough of that protein to to have that elevated mTOR all the time. So it's not something that I think that most patients should be worried about their protein intake.
Stephen Sideroff 21:54
Yeah. So just to clarify the what you were saying I was hearing two factors that you you identify in terms of the aging process. One is the proliferation of senescence cells beyond what the body is able to compensate for, or take care of, and then the turning on of tour that produces growth that is not healthy growth within the body. Yes. So So would it. Would you say that the goal is to keep tore at a healthy level? Or would you say, drive it down as much as you possibly can?
Daniel Tawfik 22:43
No, I think that I think this is really important. People understand that Tor is a good thing in in one context, and it's a bad thing. And another, its activity can be a bad thing. And another context, if you're over activating Tor. You think about a body builder, right? So body builders have as the age hair, it's known that they have a lot of cardiovascular disease, they have a lot of rates, the higher rates of cancer, because they're turning on tour all the time. And they're usually doing that by taking exogenous growth factor that are saying, Torah, lets you get more protein gets more growth. And because of that, they're growing tissue, right? They're growing, hopefully, muscle tissue to give them the aesthetic that they that they want, but they're growing all sorts of tissue, right? They're growing, they could have, you know, cancerous tissue, but they're growing, they can have senescent tissue that they're growing in that growth is it's like the air traffic controller of the cell to say grow or not grow is tore, right. And it's responding to these exogenous nutrients and growth factors. And so as you age, though, we don't want to get frail, right? That's a one of the most important factors or longevity right? So, the critical thing is to get a dose of Tor inhibition right. So that you one of the things that is very popular is this concept of a toffee G in the absence of nutrients, the cell will self clean will basically use nutrients within the cell. Basically, a lot of misfolded proteins, a lot of cellular complexes that are are debris essentially and use it for energy so that that debris is not being secreted and creating more inflammation. That is a very healthy process and that's when you get tore inactivated right? That's activity is is it's in that that air traffic controllers saying, hey, let's, let's conserve, let's use up energy, let's recycle. Now, to go in and out of those phases is really where you want to be. So I'll talk about my own life. So I do resistance training Monday through Friday, and I have gone back to eating three meals a day, I used to have two meals a day intermittent fasting. And that's because I'm in a phase of life that I needed to be, I need an extra ounce of resilience with all the stresses of running our company. And so I'm having three meals a day, and I am exercising, which should be stimulating Tor, right. But on Friday, Saturday, Sunday, Friday, I'm doing his own to work out. Saturday, we go to Will Rogers Park, my wife and I will go on a hike together. So on Friday, I'll take my rabbit myosin so that I get that dose of cellular cleaning that down regulation of growth. So I get that cleaning, right. And it's not it's something do, I don't have to take Route mice and everywhere you prefer, there's a sort of like if I need some extra resilience or being taxed by traveling too much. It's just good to get these little doses of being centrally and it's catabolic state, to to stop the acceleration of growth, and also to get that cellular deep cleaning that you can get. And it's not just the rough miser, you can get it through fasting, you can get it through Metformin. One thing that people overdo, I think, is they'll take wrath wise and they'll take Metformin they'll take, they'll take it all the time around the clock, they're always in this catabolic phase, right? They're always in this, like, let's, let's let's drive tore activity down. That's thought that doesn't necessarily mean it's the most healthy thing. There, there's going in and out of touring ambition seems to be the healthy balance that you can get from being in growth phases and being in catabolic phases. So that's my thought on that.
Stephen Sideroff 27:27
Just a quick question on the, on the regimen of taking rapa myosin, I guess we'll get into this in more detail. But I, my impression is that it's very important to do it either intermittently or once a week or something along those lines. Can you comment on that?
Daniel Tawfik 27:49
Yeah, that's absolutely right. So my wife is a transplant patient, she had lymphoma and she had a stem cell transplant, she took rapa myosin, for immune suppression, that's the label the use of rapamycin, she took it every single day to prevent her immune system from attacking her host her own tissue. That is doing it that way gets the levels the concentration of zero lameness a route bias and at a point where you're caught you're you're constantly inhibiting Tor, but you're the level there's two complexes of Tor, there's conflicts one that is gets this a top algae up regulation. And there's complex to that if the concentrations of spirulina scope high enough that you're inhibiting mTOR complex too. And that is when immune suppression starts to happen, right. And so that's a dangerous thing. You need your immune system to ward off all sorts of cancer and all sorts of viruses and so forth. So the longevity use case would be not to take it every single day because we don't want immune suppression but to get sick of weight so take it once every seven days. So I said I take my Friday I'll take six milligrams every seven days. And some weeks I don't take it I'll skip a week if I don't feel like I it's appropriate for me to take it so the you get into that short phase for about 48 to 48 hours we're getting that kind of torn ambition you're getting a toffee G you're getting the stem cell rejuvenation all that benefit of taking the rapamycin but then you get out of that favor so you get back to regular protein synthesis and growth. That's the theory behind taking it so quickly and the longevity use case.
Robert Lufkin 30:07
Yeah, that that's fascinating and very important. The dosing is is key in that obviously, let's talk about healthspan. They the telemedicine company that you found it for addressing the needs for for longevity patients. And you and Steve both alluded to issues you'd had with getting help with longevity type requests and also talk a little bit about healthspan what you do and and the services you provide.
Daniel Tawfik 30:38
Yeah, so we're a telemedicine clinic. Like I said, focus on senescence. So we again, we think senescence is a critical senescence and the the intersection of senescence and torturing and aging are a it's a pathway of it's a mechanism that is worthwhile to focus on. In terms of thinking about how do you accelerate decelerate the the aging process? We started it because of what we mentioned there was there's a dearth of providers that were super knowledgeable about what was happening in the research community. And we want it to provide patients with a home where they can discern, we have experts that can help our patient provide our patients with the latest updates, doing a meta analysis of what interventions are actually working, and what interventions are not working. Right. So we have a team of researchers on our team that will do an analysis of like, Hey, there's this new molecule, what is the research say about it? So there's that element. And so one of the problem is just there's so much noise in the wellness community, how does a patient understand what works and doesn't work? The second piece is, is just providing a place where a patient can talk to a doctor about taking drugs like rapamycin, metformin, a carbost, these mTOR inhibitors and metabolic optimizing interventions for longevity purposes, how do you take them in the context of longevity and promoting health span, we do it in such a way that they don't have to be a biohacker. And, you know, get their medication from some some lab in China or wherever. We do blood testing of our patients every six weeks to make sure they're on the right course and they're taking these medications safely. And we put them on a specific protocol, an n of one so we're by taking these getting these data points every six weeks, we can adjust their protocol. By protocol, I'm really thinking about our rapamycin protocol, which has to be very tailored to how they're responding to the medication itself. In some times we couple the rap myosin with insulin sensitizing molecules like a carbost and metformin for their longevity benefits as well. And also to kind of to, to, to modulate RAF myosin, which is has all of these these longevity benefits, but it is in some subset of our patients, insulin desensitizing. So we'd like to pair those two, the RAF myosin with a medication that kind of dampens glucose spikes like a Kerberos or Metformin. So we're looking at drugs that that are modulating the senescence pathway and we're looking at new medications that are in the pipeline that are also working. That you know, six months to 12 months from now we can be introducing terminations after we've researched and enough to say this is efficacious about that we would recommend that a patient use these medications for longevity purposes.
Robert Lufkin 34:44
Well through your company, you're one of the larger providers, I think nationwide or worldwide for rapamycin for longevity. I wonder Could you comment on your experience for side effects for rapamycin how many people We'll have to discontinue it. What side effects do you get? What are the contraindications for it?
Daniel Tawfik 35:05
Yeah, so we've had, I think three cases of we've had over 800 patients on the protocol. We've had three cases we had a patient who had some, some infection, some oral, Periodontal kind of infection that they had. We've had very few cases of infections, right because we are we are dosing the medication in a way that it's not I hypothetically if it's theoretically we're, we're not the concentration of rapamycin levels are not inhibiting mTOR complex to to get the immune suppression. So that is to say it's been Barry said the safety profile a wrap myosin as scary as rapamycin sounds of the labeled indication of suppressing the immune system is far more safe than even we imagined starting starting the protocol itself. So we've had three patients that we had to discontinue our doctors and it's not appropriate for you to take this medication out of our over 800 patients that have taken it, we do see So like I mentioned insulin desensitizing aspects of taking rapamycin in some patients so we'll see elevations and glucose levels. In those cases, we do pair pair the the rapamycin uses with a carbost or mat forming in some patients, we do see elevated lipids as well. So there's there's lifestyle body modifications, we can do or complete disconnect continuation of taking rapamycin. Or in some cases, though, patients will elect to take a statin.
Robert Lufkin 37:08
And I have to ask sort of the other side of the coin. So there's relatively few few side effects or contraindications. The challenge for for all these longevity interactions is to figure out how they're working. So what do you use to assess that the rapamycin is actually doing anything? And what sort of effects have you noticed in your patients,
Daniel Tawfik 37:32
we're, you know, I'd say this is the aspect of the protocol. We're we're doing we're doing the Levine testing every six months, we're doing a metabolic profile plus all of like the insulin, albumin, all of the things are in the Lavy. If you look at if anyone wants to do a search for the biological age calculator, we're seeing a reduction, we we send a requisitions every six weeks for that test. And we do a calculation of how biological age is being moved in any direction. And we're seeing a reduction in biological age of for every three months of usage, it's about two and a half years. So that's that's really promising. However, I want to say that test is we don't have the greatest tools right now to measure how much of the senescence burden is being reduced. With that being said, in the next six months, we're going to be partnering with a group that has some more precise testing on senescence. The problem with these tests is they're very expensive, they're in the range of like $500. So our goal is to make these these diagnostic tools have enough scale with our program that we can drive down pricing of them and kind of continue to measure their efficacy. These are very kind of novel new tests, and we were you know, they haven't been used at scale to really, to really justify their their efficacy as a as a diagnostic tool. So with that is to say we will have some more senescence testing that we will be releasing in the next six months and we're trying to be more precise with the diagnostic aspects of our program. Right now. We're using very, very basic tools that your patients can any patient who's listening can go after doctor for a metabolic profile, get the results, get the results of that test, and then put the results that test until biological age calculator and get the results for themselves.
Stephen Sideroff 40:05
So a couple of basic questions here. Your measure, you're making comments about cost. Is any of this covered by insurance. And I'm assuming that this does not replace someone's primary physician.
Daniel Tawfik 40:23
That's absolutely right. So, yeah, we're not we're not, we don't we don't substitute a PCP visit, right. So we we, we are this kind of additional layer of care for people who are interested in longevity protocols, right. So it's telemedicine based so we can provide the level of care that you need when you're having an acute health crisis, right. The aspect of is it covered by insurance? I know in some patients, it is covered by insurance, the rapamycin itself. So we can prescribe rapamycin, ultimately, whether the insurance company covers the the cost of the wrap myosin is, is gotten a case by case basis. It's usually not. I know, some people I've talked to, we've talked about this, you know that it is covered, I think, for yourself. But we're a cash based business right now. Because we we're in the position where we work with doctors in 50 states. And we're not we don't want to imposition them with calls from the insurance company trying to justify why they're putting their patients on a immune suppressant drug. Right. So we're, we're cash base at the moment.
Stephen Sideroff 41:59
Do you have any opinion about take na d Have you thought about an ad is one of what you offer?
Daniel Tawfik 42:08
We don't offer it primarily because we don't think there's any efficacy in taking it there's there's it's not clear that it gets absorbed in the form of an ad, the actual end product and molecule and at taking it through IV or through any other module. We also don't prescribe nr or mn cos the same reasons we're not sure that it actually gets absorbed into the place that needs to be outside of the liver, perhaps but so we would, that's one thing, we only prescribe with about three medications because we're convinced that they that they push the needle in terms of longevity, if we do not, we're not a wellness company in that sense, where it's like every supplement known to man will will sell if there's no efficacy, we will. We will recommend it to our patients.
Robert Lufkin 43:12
What are you most excited about in this space? Daniel, either with healthspan as a company or the field in general?
Daniel Tawfik 43:20
I think it's what I'm most excited about is this summer, we saw the biggest growth. And that was because people like Peter, Tia, people like yourself, people like Tim Ferriss, we're talking about rapamycin. Before we were kind of in this like, you know, early adopter weirdo world, like, you know, we have this small community, we talk about it, and we're kind of like a very niche niche world. And I feel like we're kind of going mainstream with through your work, essentially, with the work of Peter Thiel, who are talking about this and making making these therapeutics, more well known sets that like, I'll bring it close to home. My mom used to think, like, what are you taking these medications for? And now she's like, Oh, is it do you think I should start taking them and she's very conservative in that regard. So it's very exciting to see this gradually becoming more mainstream. From a from a therapeutic standpoint, I think the idea of analytics, so drugs that target senescence cells, it seems very interesting. The efficacy of them the knowing it seeing them come to market, is I think we're very far away from that. But that seems seems very interest stain, there's a use case of one right now called the satin nib, that some patients, I've never taken it, but people have noticed some very positive benefits from it. That's a set of lytic. That's very interesting, but it's definitely not something we're going to be prescribing. You know, you you bring this up in your presentation, the rich Miller ITP, the the medications that showed efficacy, and the a Kerberos, the kind of the GLP, one medications are optimized, and to see them become more of a mainstream, more well known and more well prescribed in the mainstream, it would be very interesting to me.
Stephen Sideroff 45:56
So this is a fascinating subject, and the work you're doing is really great. I think it's kind of pushing the helping to push the envelope. Can you give our listeners how they can reach you what your website is?
Daniel Tawfik 46:13
Yeah, absolutely. So if you were found online, you go to get health span.com. So to get health span, and if you let us know that doctor, love Canada Brazilian podcast, referred, you will provide you guys with a $60 discount. And I think in the show, we'll send you both the link to the signup form or the patient's can retrieve their discount. So just get healthspan.com. And you would just sign up, you don't pay anything upfront, you would speak to a doctor, if the medication is appropriate for you, then you would get charged for for the protocol itself. You can find us on Twitter, we're always sharing healthspan bad we're always sharing the latest research. And then we also have a community at Community dot get healthspan.com or sharing. We're sharing the latest information on the latest research.
Robert Lufkin 47:13
Great, thanks. Thank you, Daniel. We'll include that information in the show notes for our for our audience. But thanks again, Daniel, for taking an hour of your time to spend with us and talk about the great work you're doing and and thanks for your your interest in this field.
Daniel Tawfik 47:31
Oh, thank you, you guys. Really what you're doing such a service to, to making this palatable to, you know, the patients that we discussed prior to this podcasts are not these early adopter types. These are more mainstream people that are hearing, your podcasts, your your lectures, it's really having a profound impact. So I think kudos to you.
Unknown Speaker 47:58
Thank you, thank you. This is for general information and educational purposes only, and is not intended to constitute or substitute for medical advice or counseling, the practice of medicine or the provision of health care, diagnosis or treatment, or the creation of a physician, patient or clinical relationship, the use of the separations of their own own users risks. If you find this to be on the value of please hit that like button to subscribe to support the work that we do on this channel. And we take the your suggestions and advice very seriously, so please let us know what you'd like to see on this channel. Thanks for watching and we hope to see you next time